Austedo

Drug Teva Pharmaceuticals USA, Inc.
Total Payments
$1.2M
Transactions
1,383
Doctors
13
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $398,535 895 12
2018 $753,938 488 1

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.2M 1,382 100.0%
Education $57.50 1 0.0%

Payments by Type

Research
$1.2M
1,382 transactions
General
$57.50
1 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Teva Pharmaceuticals USA, Inc. $855,323 0
An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease Teva Pharmaceuticals USA, Inc. $215,581 0
A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Teva Pharmaceuticals USA, Inc. $81,512 12

Top Doctors Receiving Payments for Austedo

Doctor Specialty Location Total Records
Unknown Miami, FL $1.1M 1,308
, MD Specialist Tampa, FL $3,090 6
, D.O Neurology with Special Qualifications in Child Neurology Birmingham, AL $2,480 6
, M.D Neurodevelopmental Disabilities Birmingham, AL $2,286 8
, M.D Neurology with Special Qualifications in Child Neurology Miami, FL $2,122 6
, M.D Neurology with Special Qualifications in Child Neurology Rochester, NY $2,102 6
, M.D Neurology with Special Qualifications in Child Neurology Phoenix, AZ $1,953 6
, M.D Neurodevelopmental Disabilities Nashville, TN $1,808 6
, M.D Pediatrics Houston, TX $1,800 2
, M.D Neurology with Special Qualifications in Child Neurology Houston, TX $1,782 7
, MD Neurology with Special Qualifications in Child Neurology Voorhees, NJ $1,766 6
, M.D Neurology Nashville, TN $1,560 8
, MD Neurology with Special Qualifications in Child Neurology Atlanta, GA $680.85 7
, M.D Addiction Psychiatry Myrtle Beach, SC $57.50 1

About Austedo

Austedo is a drug associated with $1.2M in payments to 13 healthcare providers, recorded across 1,383 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..

Payment data is available from 2018 to 2019. In 2019, $398,535 was paid across 895 transactions to 12 doctors.

The most common payment nature for Austedo is "Unspecified" ($1.2M, 100.0% of total).

Austedo is associated with 3 research studies, including "An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia" ($855,323).